Imvlo 5 mg purutabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

imvlo 5 mg purutabletti

n.v. organon - montelukast sodium - purutabletti - 5 mg - montelukasti

Imvlo 4 mg purutabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

imvlo 4 mg purutabletti

n.v. organon - montelukast sodium - purutabletti - 4 mg - montelukasti

Imvlo 4 mg rakeet Suomi - suomi - Fimea (Suomen lääkevirasto)

imvlo 4 mg rakeet

n.v. organon - montelukast sodium - rakeet - 4 mg - montelukasti

MONTELUKAST NAVAMEDIC 4 mg purutabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

montelukast navamedic 4 mg purutabletti

navamedic asa - montelukastum natricum - purutabletti - 4 mg - montelukasti

MONTELUKAST NAVAMEDIC 5 mg purutabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

montelukast navamedic 5 mg purutabletti

navamedic asa - montelukastum natricum - purutabletti - 5 mg - montelukasti

MONTELUKAST NAVAMEDIC 10 mg tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

montelukast navamedic 10 mg tabletti

navamedic asa - montelukastum natricum - tabletti - 10 mg - montelukasti

Fampridine Accord Euroopan unioni - suomi - EMA (European Medicines Agency)

fampridine accord

accord healthcare s.l.u. - fampridine - multippeliskleroosi - muut hermoston huumeet - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Sitagliptin SUN Euroopan unioni - suomi - EMA (European Medicines Agency)

sitagliptin sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Artesunate Amivas Euroopan unioni - suomi - EMA (European Medicines Agency)

artesunate amivas

amivas ireland ltd - artesunate - malaria - antiprototsooisia - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. on otettava huomioon viralliset ohjeet antibioottien asianmukaisesta käytöstä malarian aineet.

Fampridine Stada 10 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

fampridine stada 10 mg depottabletti

stada arzneimittel ag - fampridine - depottabletti - 10 mg - fampridiini